Celdara Medical
Celdara Medical transforms early-stage academic innovations into high-potential medical companies, bridging discovery and profitability.
Founded
2008Celdara Medical transforms early-stage academic innovations into high-potential medical companies, bridging discovery and profitability.
celdaramedical.comCrawled Oct 16, 2026
ImmuType, a Celdara Medical enterprise, focuses on systemic autoimmune disease and uses molecular profiles to stratify patients and identify treatment responders, aiming to improve clinical trial success and reduce trial time and cost.
The company collaborates with the inventor to determine scientific, preclinical, clinical, and regulatory strategies.
ImmuType can improve the success rate, while reducing time and cost of clinical trials. Beyond enrollment, ImmuType can also support retrospective analysis of patient samples to garner pathway and mechanism of action (MoA) insights and inform clinical and market strategy.
The page questions the timing of developing life-saving medicines against infectious diseases, comparing it with designing weapons after war is declared.
Listen to the Financing to Proof of Concept & Term Sheet Discussion lecture by David Darst, COO at Rgenix.
Listen to the 'How to ‘Value’ an Early Stage Asset: Discount Cash Flow Analysis for Early Stage Assets' Lecture by Sam Hall, Principal at Apple Tree Partners.
Listen to the Introduction to Open Innovation lecture by Celdara Medical.
Celdara Medical, LLC today announced that the National Cancer Institute of the National Institutes of Health has awarded a two-year, $2 million Phase II Small Business Innovation Research grant to fund the company’s development of a B cell focused immunotherapy to treat melanoma and other cancers.
Celdara Medical, LLC today announced that it has been recognized as the fastest growing company in the State of New Hampshire by Business NH Magazine.
Celdara Medical, LLC today announced that it has successfully concluded negotiations with Celyad SA (Euronext Brussels and Paris, and NASDAQ:CYAD) related to their ongoing partnership for discovery and development of CAR T cell therapies.
Celdara Medical, LLC announced today that it has received national recognition from the Small Business Administration (SBA) in the form of a Tibbetts Award. The award recognizes unique contributions to the Small Business Innovation Research (SBIR) Program.
Celdara Medical seeks outstanding scientists with interest in translational research and biotechnology for a paid Fellowship. Prior Fellows have jumpstarted careers in Venture Capital, Management Consulting, Technology Transfer, R&D, Medical Writing, and Business Development.
Celdara seeks an entrepreneur in residence to identify assets from its portfolio or incoming innovation pipeline, develop a new company or partnership opportunity and strategy, and spin out and raise funding within 6-24 months.
The Grants Manager and Administrative Specialist role is in Lebanon, NH, with a starting salary of $70,000; Celdara Medical is building early-stage medical companies with academic collaborators.
A Celdara Medical team member helps develop early-stage innovations into treatment options and works with scientific founders to plan and operationalize program processes.
Meeting the team behind Celdara Medical who help advance Programs with the potential to transform human health in a creative, fast-paced and entrepreneurial environment.
Celdara Medical describes its corporate social responsibility work through people, planet, and patients, with philanthropic priorities set by its team.
Celdara Medical develops academic and early-stage innovations into medical companies, partners with inventors and institutions, and provides developmental, financial, and business support to move discoveries toward market.
Celdara Medical works with selected partner institutions and is not currently working with individual inventors outside its networks.
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world’s most challenging diseases.